It will be important to determine whether the beneficial effects of short-term OX40 agonist immunotherapy during early infection can be improved upon with extended treatments during chronic infection, or on the contrary, if repeated stimulation is detrimental, potentially by driving T cell exhaustion or immunopathology. The gene discussed is TNFRSF4; the disease is infection.